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combinant adenovirus with subsequent infection in the C2C12 embryonic mus-
cle cell line. A tetracysteine site, which enables site-specific labeling of the
fluorescein biarscenical hairpin-binding dye (FlAsH), was introduced in the up-
per 50 kDa (U50) region (residues 316-321) corresponding to the previously
utilized site in myosin V. Key conformational changes in the myosin motor,
including those associated with nucleotide and actin binding, can be examined
by fluorescence resonance energy transfer (FRET) using M2B-S1 FlAsH and
fluorescent nucleotides or IAEDANs-labeled actin. We demonstrate the enzy-
matic properties of M2B-S1 FlAsH are similar to unlabeled M2B-S1, and both
are capable of moving actin filaments in the in vitromotility assay. We utilized
FRET between M2B-S1 FlAsH and Cy3ATP to examine structural changes in
the U50 domain. The kinetics of structural changes were examined during the
ATP-binding and actin-activated product release steps. We also designed a sys-
tem to study structural changes in the force-generating lever arm using FlAsH
labeling at the N-terminus of a human b-cardiac myosin construct containing a
C-terminal GFP (M2B-GFP). The spectroscopic approach can be used as a tool
to study the effects of hypertrophic cardiomyopathy (HCM) mutations on
myosin structure or to study the impact of drugs that alter myosin motor
activity.
2840-Pos Board B532
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Embryonic (MYH3), perinatal (MYH8), and alpha (MYH6) myosin heavy
chains are predominantly expressed during prenatal development of human
skeletal and cardiac muscle and may be upregulated following injury. To
determine how mutations in these genes affect performance, development,
and injury recovery, it is important to understand the contractile properties
of the human fetal muscle in which these isoforms are dominant. However,
information on developing human skeletal and cardiac muscle is limited.
We previously reported that human fetal skeletal muscle from a single fetus
of ~16 weeks gestation had slower crossbridge cycling myosin compared to
adult rabbit psoas myosin (in vitro motility measurements) and slower myofi-
bril activation & relaxation kinetics accompanying weaker force production
than adult human skeletal myofibrils (Racca et al. (2013) J.Phys 591:3049-
3061). Here we characterized and compared the contraction and relaxation
properties of human fetal skeletal (HFS) and cardiac (HFC) muscle from
fetuses of ~16 weeks gestation using myofibril mechanics techniques.
HFC muscle was isolated and used fresh, while HFS muscle was flash-
frozen in liquid nitrogen prior to use. The HFC myosin propelled unregulated
F-actin filaments 49% slower than HFS myosin (HFC:1.6650.13mm$s1;
HFS:2.6450.02mm$s1) (2mM ATP, 30C). During maximal calcium
activation (15C), HFC myofibrils produced more force (FMAX=
10.553.6mN/mm2) than HFS (5.951.2mN/mm2), at slightly slower rates
(HFC:kACT=0.4650.09s
1; HFS:0.6650.10s1). The initial (slow) phase of
relaxation was slightly longer in duration (HFC:tREL,slow=203527ms;
HFS:174513ms), and slower in slope (HFC:kREL,slow=0.2650.03s
1;
HFS:0.5950.15s1), indicating slower crossbridge release which may also be
influenced by troponin regulation. The secondary (fast) phase of relaxation
was similar (HFC:kREL,fast=1.850.2s
1;HFS:1.550.2s1). Research to charac-
terize the contractile properties of early development muscle and myosin heavy
chain isoforms is ongoing, and may elucidate their role in development and
muscle repair. Supported by F31AR06300(A.R.), 5K23HD057331(A.B.),
HD048895(M.B.,M.R.).
2841-Pos Board B533
Improved Loaded In Vitro Motility Assay and Actin Filament Tracking
Software Delineates the Effect of Hypertrophic and Dilated Cardiomyop-
athy Mutations on the Power Output of Cardiac Myosin
Tural Aksel, Masataka Kawana, Arjun Adhikari, Shirley Sutton,
Kathleen Ruppel, James Spudich.
Biochemistry, Stanford University, Stanford, CA, USA.
Hypertrophic (HCM) and dilated (DCM) cardiomyopathies are important
causes of heart failure, arrhythmia, and sudden cardiac death. HCM is the
most common heritable cardiovascular disorder, affecting 1 in 500 individ-
uals, and is caused primarily by mutations that alter proteins of the cardiac
sarcomere. Sarcomeric protein mutations are an increasingly recognized cause
of familial DCM as well. HCM is associated with severe thickening of the leftventricular wall, preserved/increased systolic (contractile) and impaired dia-
stolic (relaxation) function of the heart. DCM hearts have dilated left ventric-
ular chambers and suffer from inadequate systolic activity. More than 300
point mutations in beta-cardiac myosin are associated with HCM or DCM.
It is believed that HCM and DCM mutations increase and decrease respec-
tively the power output of cardiac myosin which leads to a cascade of down-
stream signaling that gradually leads to the disease phenotype. To test this
hypothesis it is essential to measure the power output of all HCM/DCM mu-
tants in a high throughput manner. To quantitatively measure the load depen-
dent myosin power output, we first improved the loaded in vitro motility assay
(LIMA) by replacing load generating molecule alpha-actinin with alpha-
catenin, which was generously provided by James Nelson at Stanford Univer-
sity. For accurate-and-fast data analysis, we developed a software called
FAST that runs over parallel CPUs. Our initial results indicate that two
HCM mutants (R719W, R403Q) have higher power output than the wildtype
cardiac myosin. FAST-LIMA will be an essential tool for screening drugs that
revert the effects of HCM/DCMmutations on the power output of beta-cardiac
myosin.
2842-Pos Board B534
Modulation of the Cardiac Sarcomere by a Small Molecule Agent
MYK0000461: A Potential Therapeutic for the Treatment of Genetic Hy-
pertrophic Cardiomyopathies
Hector M. Rodriguez1, Stephanie Whitman-Cox1, Raja Kawas1,
Yonghong Song2, Arvinder Sran2, Johan Oslob2.
1Biology, MyoKardia, Inc., South San Francisco, CA, USA, 2Chemistry,
MyoKardia, Inc., South San Francisco, CA, USA.
We have identified a small molecule inhibitor, MYK0000461, of the cardiac
myosin ATPase. This agent was characterized in steady state and transient ki-
netic assays to understand its mechanism of action. MYK0000461 decreases
the steady-state rate of the ATPase activity of purified bovine b-cardiac myosin
subfragment-1 (S1) as well as that of bovine cardiac myofibrils, wild type and
the mutant R453C of recombinant human b-cardiac myosin S1. We also find
that MYK0000461 inhibits cardiac myosin selectively as compared to systems
containing rabbit skeletal or chicken smooth muscle myosins Analysis of the
individual steps of the chemo-mechanical cycle of cardiac myosin suggests
that MYK0000461 exerts its effect by inhibiting the actin-stimulated release
of phosphate, presumably by stabilizing the detached state of cardiac myosin
prior to the release of phosphate. We find no evidence to suggest that
MYK000461 inhibits cardiac myosin in a strongly bound state and no other
steps in the chemo-mechanical cycle are affected by MYK0000461. Thus,
the enzymatic step governing the weak to strong transition of S1 binding to
actin is inhibited without affecting the release from the strongly bound states.
This decrease in the rate of transition from the weak to strongly bound state
should decrease force production and may underlie its ability to decrease car-
diac contractility in cellular and in vivo models of cardiac function. An agent
such as MYK0000461 could potentially be used to treat cardiac disorders
that stem from hyper contractility such as the genetic hypertrophic cardiomy-
opathies (HCM). By decreasing the net force of contraction and restoring it
back to normal level could potentially be useful in treating patients that suffer
from this disease.
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The small molecule omecamtiv mecarbil (OM), currently in late phase-2 clin-
ical trials for treatment of heart failure, activates force generation by cardiac
myosin. How OM increases force generation is not known. Crosslinking and
molecular docking studies suggest that the compound binds to the relay/SH1/
converter region of myosin, hypothesized to control the actin-activated pre to
post power-stroke structural transition in the myosin catalytic and light-chain
domains. These transitions drive force production by myosin. We are currently
using time-resolved FRET and EPR distance measurements to detect the pre-
and post-power-stroke structural states of myosin. We have performed these
studies on tissue-purified b-cardiac and a-skeletal myosin, and on a recombi-
nant cys-lite myosin II catalytic domain model from Dictyostelium discoideum.
In each of the myosin isoforms, we find that OM binding increases the mole
fraction of the myosin post power-stroke structural state in the presence of
ATP analogs. Transient time-resolved FRET experiments, mixing FRET-
labeled myosin with ATP, show that drug binding also alters the structural ki-
netics of the myosin recovery-stroke. Ongoing studies are investigating the
Tuesday, February 18, 2014 563aaffect of OM on the actin-activated power-stroke. These results show that OM
has a direct effect on the power-stroke structural transition that drives force
generation in muscle, thus providing structural insight into the mechanism of
this new potential therapy for heart failure. Our results also highlight the utility
of structure-based time-resolved FRET and EPR assays for the discovery and
characterization of allosteric enzyme modulators.
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It has been demonstrated that the phosphorylation of the RLC can also aid in
the attachment of myosin heads to actin. Moreover, it has been demonstrated
that phosphorylation of the RLC is altered during heart failure progression.
Here we examined the role of the RLC, and its phosphorylation, on the
motility of a and b Myosin. We characterized the strain dependent kinetics
of both myosins by analyzing the dependence of velocity on load using
increasing amounts of a-actinin up to 10 mg/ml. As expected, a-myosin,
both phosphorylated and dephosphorylated, had a faster actin sliding velocity
than b-myosin over the majority of a-actinin concentrations, while phosphor-
ylation of the b-myosin had no significant impact on the actin sliding velocity.
Interestingly, although phosphorylation of
a-myosin significantly reduced the un-
loaded sliding velocity it, increased veloc-
ity under loaded conditions (See Figure).
These results suggest that the phosphory-
lation of the RLC acts at the molecular
level to stiffen the lever arm of myosin
aiding in both myosin head attachment
and power stroke.2845-Pos Board B537
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Familial Hypertrophic Cardiomyopathy (FHC) is characterized by left ven-
tricular hypertrophy that can often be preceded by diastolic dysfunction. The
clinical presentation of the disease varies from asymptomatic to progressive
heart failure to sudden cardiac death. FHC is caused by mutations in genes
that encode for all major sarcomeric proteins. There are 12 known FHC-
linked mutations in the myosin regulatory light chain (RLC). The RLC
mechanically stabilizes the myosin lever arm, which is crucial to myosin’s
ability to transmit contractile force. Two FHC mutations, N47K and R58Q,
located in the RLC Ca2þ-Mg2þ site have previously been shown to reduce
actin filament velocity under load, stemming from a more compliant lever
arm (Greenberg et al., PNAS add details 2010). In contrast, phosphorylation
of the RLC can impart stiffness to the myosin lever arm. We hypothesized
that phosphorylation of the N47K-RLC may mitigate distinct mutation-
induced structural and functional abnormalities. To generate mutant
b-myosin, native pig RLC was depleted from porcine cardiac myosin
heavy chain and reconstituted with mutant N47K or wild-type human
RLC. In the work presented here, in vitro motility assays were utilized to
investigate the effects of RLC phosphorylation on the N47K-RLC mutant
phenotype in the presence of an a-actinin frictional load. Consistent with
previous findings, myosin bearing the N47K mutation reduced actin sliding
velocity compared to WT when incubated with a-actinin, resulting in a 25%
reduction in force production. Phosphorylation of N47K mutant myosin
increased sliding velocity and restored force production to WT values.
These results point to RLC phosphorylation as a potential target to amelio-
rate the FHC RLC phenotype at the molecular level. Supported by AHA-
12PRE11910009 (AK), 10POST3420009 (PM), NIH- HL071778 &
HL108343 (DSC) and HL077280 (JM).
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Cardiac and skeletal muscle myosins have the central role in contraction
transducing ATP free energy into the mechanical work of moving actin intransduction/mechanical coupling. Inheritable cardiomyopathies are more
frequently linked to myosin mutations than other sarcomeric proteins. Hered-
itary skeletal myopathies linked to myosin are less common. They lead to
muscle weakness or affect myosin isoforms expressed during development
leading to arthrogryposis syndromes. Myosin has a motor domain containing
ATP and actin binding sites and light chains stabilized lever-arm that un-
dergoes rotation impelling bound actin. The lever-arm converts torque gener-
ated in the motor into linear displacement (step-size). Relative myosin and
actin filament sliding is modeled in vitro with a motility assay quantitating
actin filament translation over a myosin coated surface. A novel quantum
dot super-resolution in vitro motility assay confirmed a 5 nm step-size for
fast skeletal myosin while b cardiac myosin (bMys) had multiple unitary
steps, most frequently 5 and 8 nm, and a rare 3 nm displacement. The myosin
lever-arm is stabilized by bound essential and regulatory light chains (ELC
and RLC). RLC phosphorylation at S15 is linked to modified lever-arm me-
chanical characteristics contributing to disease and to myosin filament based
contraction regulation. We have studied the effect of RLC phosphorylation on
the step-size of porcine bMys. Phosphorylated bMys has ~85% of the myosin
phosphorylated. We find RLC phosphorylation causing the distribution of
longest step increasing from 37% to 71%. This dramatic re-distribution of
step-sizes provides significant gain in average step-size. The results indicate
a mechanism for contraction regulation by step-size adaptation using post-
translational modification of the myosin filament via RLC phosphorylation.
Research supported by R01AR049277, R01HL095572 and the Mayo
Foundation.
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The effect of A13T (alanine to threonine) hypertrophic cardiomyopathy mu-
tation in the myosin regulatory light chain (RLC) was examined in working
ex-vivo myofibrils from the hearts of transgenic (Tg) mice. Myofibrillar
actin was labeled with a fluorescent dye. A small volume within the
I-band (?1 fL), containing on average 3-4 actin molecules, was observed
by confocal microscopy. The myofibrils were cross-linked with EDC
[1-ethyl-3-[3-(dimethylamino) propyl] carbodiimide] to prevent shortening
during muscle contraction. Working myosin cross-bridges cause actin to un-
dergo the cyclic fluctuations of orientation, which were measured by
recording the polarization of fluorescent light emitted by the actin-bound
fluorophore. The autocorrelation function of fluctuations of polarized fluo-
rescence contains information about the kinetics of motion, which were
found to be very different for left vs. right ventricles. The center of distri-
bution of orientations of transition dipoles during contraction were very
different for the Wild Type (WT) and mutated (MUT) ventricles, but their
skewness and kurtosis were the same. The distribution of orientations
measured in contracting WT myofibrils could be fitted by at least two
Gaussians reflecting a pre- and post power stroke states of the myosin
cross-bridges. However, the distribution of MUT myofibrils showed only
one Gaussian relationship suggesting that the hypertrophic phenotype asso-
ciated with the A13T-RLC mutation might be characterized by a loss of the
pre-power stroke state.
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Cross-bridge (XB) kinetics and the degree of order were examined in con-
tracting myofibrils from the ex-vivo left ventricles of transgenic (Tg) mice
expressing Familial Hypertrophic Cardiomyopathy (FHC) Regulatory Light
Chain (RLC) mutation K104E. Since the kinetics and degree of order are
best studied when an individual XB makes a significant contribution to the
